Several factors, including decreased activities of lipoprotein lipase and lecithin cholesterol acyltransferase (LCAT) and decreased hepatic lipase levels, promote dyslipidemia development in chronic kidney disease patients. This evidence concerns the gene LCAT and chronic kidney disease.